Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxycodone IR Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

NCT03802227
View directory record Official record
Conditions
Moderate to Severe Chronic Pain
Interventions
NKTR-181, Oxycodone IR
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT01016808
View directory record Official record
Conditions
Moderate to Severe Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

NCT01280331
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 4, 2026, 11:14 AM EDT
Terminated Phase 4 Interventional Results available

Open-Label Trial Comparing Oxycodone Medications

NCT01162304
View directory record Official record
Conditions
Chronic Pain
Interventions
Extended Release Oxycodone, Immediate Release Oxycodone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
View directory record Official record
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 4, 2026, 11:14 AM EDT
Completed No phase listed Observational

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

NCT04033094
View directory record Official record
Conditions
Baseline Epidemiologic Assessment
Interventions
MorphaBond ER, Comparator Drug
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Not listed
Enrollment
17,566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

NCT00986180
View directory record Official record
Conditions
Pain, Back Pain, Low Back Pain, Back Pain With Radiation
Interventions
NUCYNTA, Oxycodone IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans

NCT01500317
View directory record Official record
Conditions
Effects of 2 Mu-opiates on Gastrointestinal Transit
Interventions
Tapentadol, Oxycodone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

NCT00818493
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT00831051
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nasal Human Abuse Potential of PTI-821

NCT03475862
View directory record Official record
Conditions
Opioid Abuse Nondependent
Interventions
PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone
Drug · Other
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

NCT01055015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, PD and PK Study in Healthy Adults

NCT02211625
View directory record Official record
Conditions
Healthy
Interventions
Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

NCT04310579
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 4, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533
View directory record Official record
Conditions
Arthroplasty
Interventions
Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 4, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 4, 2026, 11:14 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 4, 2026, 11:14 AM EDT